(Total Views: 587)
Posted On: 06/19/2017 5:06:29 PM
Post# of 72440
New QUINOLONE approved against ABSSSI. Let's remember, this is an exceedingly dangerous class of antibiotics which the FDA just put a black box label on (Cipro, Avelox, Levaquine, and their generics) saying that they were so dangerous they should only be used when their is risk of death without using them.
So great, glad there is something new to use, but, geeze, remember I've mentioned several times about someone I know who took ONE dose of Cipro and is now permanently disabled, in a wheelchair and having to take anti-seizure medications. ONE DOSE of Cipro.
So I'm not impressed by this new antibiotic. If Brilacidin for ABSSSI is approved, it will certainly be used first, before dangerous life-threatening quinolones are used.
So great, glad there is something new to use, but, geeze, remember I've mentioned several times about someone I know who took ONE dose of Cipro and is now permanently disabled, in a wheelchair and having to take anti-seizure medications. ONE DOSE of Cipro.
So I'm not impressed by this new antibiotic. If Brilacidin for ABSSSI is approved, it will certainly be used first, before dangerous life-threatening quinolones are used.
Quote:
The FDA approves privately-held Melinta Therapeutics' Baxdela (delafloxacin), a fluoroquinolone antibiotic, for the treatment of adults with acute bacterial skin and skin structure infections ((ABSSSI)).
Baxdela had Qualified Infectious Disease Product (QIDP) status which provides for an additional five-year period of market exclusivity for the indication.
(0)
(0)
Scroll down for more posts ▼